GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy

International Journal of Cancer

Volumn 128, Issue 3, 2011, Pages 726-731

  Lee, Eunjung ^a   Nichols, Peter ^a   Groshen, Susan ^a   Spicer, Darcy ^a   Lee, Amy S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

adjuvant chemotherapy; breast cancer; GRP78; predictive marker; taxane

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GLUCOSE REGULATED PROTEIN 78; PACLITAXEL; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; MASTECTOMY; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; LYMPHATIC METASTASIS; MENOPAUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PACLITAXEL; PREDICTIVE VALUE OF TESTS; TAXOIDS; TREATMENT OUTCOME;

EID: 78649874180     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25370     Document Type: Article

References (20)

1. American Cancer Society. Breast cancer facts and figures 2007-2008. Atlanta, GA: American Cancer Society, Inc.
2. Ries LA, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, et al. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute, 2008;, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
4. Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, Natoli G, Terzoli E, Cognetti F, Giannarelli D,. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006; 106: 2337-44.
5. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK,. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007: CD004421.
6. Marchionni L, Wilson RF, Wolff AC, Marinopoulos S, Parmigiani G, Bass EB, Goodman SN,. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med 2008; 148: 358-69.
7. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357: 1496-506.
8. Lee AS,. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 2007; 67: 3496-9.
9. Li J, Lee AS,. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006; 6: 45-54.
10. Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA,. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 2006; 66: 1702-11.
11. Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS,. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007; 67: 9809-16.
12. Virrey JJ, Dong D, Stiles C, Patterson JB, Pen L, Ni M, Schönthal AH, Chen TC, Hofman FM, Lee AS,. Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res 2008; 6: 1268-75.
13. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS,. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 2003; 278: 20915-24.
14. Fu Y, Li J, Lee AS,. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen-starvation induced apoptosis. Cancer Res 2007; 67: 3734-40.
15. Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS,. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 2006; 66: 7849-53.
16. Vahdat L,. Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin? Nat Clin Pract Oncol 2008; 5: 570-1.
17. Shi SR, Cote RJ, Taylor CR,. Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem 1997; 45: 327-43.
18. Munro S, Pelham HR,. An Hsp70-like protein in the ER: identity with the 78 kD glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell 1986; 46: 291-300.
19. Kalbfleish J, Prentice R,. The statistical analysis of failure time data. New York: Wiley, 1980.
20. Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, Ma WY, Bode AM, Dong Z,. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 2006; 66: 9260-9.